Publication Name	World Journal of Gastroenterology
Manuscript ID	29003
Country	Sweden

Received	2016-07-25 09:48
Peer-Review Started	2016-07-26 11:46
To Make the First Decision	2016-09-12 17:05
Return for Revision	2016-09-13 08:26
Revised	2016-09-18 22:26
Second Decision	2016-10-14 18:07
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-10-19 17:31
Articles in Press	2016-10-19 17:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-11-08 17:58
Publish the Manuscript Online	2016-11-18 15:13

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Surgery
Manuscript Type	Review
Article Title	Immune checkpoint therapy for pancreatic cancer
Manuscript Source	Invited Manuscript
All Author List	Henrik Johansson, Roland Andersson, Monika Bauden, Sarah Hammes, Stefan Holdenrieder and Daniel Ansari
Funding Agency and Grant Number
Corresponding Author	Daniel Ansari, MD, PhD, Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, SE-221 85 Lund, Sweden. daniel.ansari@med.lu.se
Key Words	Pancreatic cancer; Immune checkpoint inhibitors; Clinical trials
Core Tip	Immunotherapy is a rapidly expanding field within pancreatic cancer research. Here we summarize the effectiveness of immune checkpoint inhibition in the treatment of pancreatic cancer, focusing on the anti-tumor response and toxicity of drugs targeting cytotoxic T lymphocyte antigen 4, programmed cell death 1 and programmed cell death ligand 1. Based on the results from small series it appears that immune checkpoint inhibitors may be safe and effective, but still little published evidence is available to prove or disprove the clinical benefit of these drugs in patients with pancreatic cancer. Several well-designed clinical trials are ongoing and the results from these trials are eagerly awaited.
Publish Date	2016-11-18 15:13
Citation	Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol 2016; 22(43): 9457-9476
URL	http://www.wjgnet.com/1007-9327/full/v22/i43/9457.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i43.9457

Full Article (PDF)	WJG-22-9457.pdf
Full Article (Word)	WJG-22-9457.doc
Manuscript File	29003-Review.docx
Answering Reviewers	29003-Answering reviewers.pdf
Audio Core Tip	29003-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	29003-Conflict-of-interest statement.pdf
Copyright License Agreement	29003-Copyright assignment.pdf
Peer-review Report	29003-Peer-review(s).pdf
Scientific Misconduct Check	29003-Scientific misconduct check.pdf
Scientific Editor Work List	29003-Scientific editor work list.pdf